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It is well known that the activation of Aurora A/B (Aur A/B) or inactivation of BRCA1/2 induces tumor formation.
Others and we have reported that the mutual suppression between Aur A/B and BRCA1/2 may manipulate cancer
cell growth and tumorigenesis, however, the interactive regulation and mechanism between these molecules are
still elusive. In this study, by consecutive silencing of Aur A/B or/and BRCA1/2 with specific shRNAs, we showed
that, in BRCA2-deficient pancreatic cancer cell line Capan-1 and in ovarian cancer cell line OVCA433, Aur A/B and
BRCA1/2 inversely regulated the expression of each other likely through proteasome-mediated proteolysis but not
through gene transcription. Aur A/B and BRCA1/2 conversely regulated cell cycle progression mainly through
control of p53 and cyclin A. Moreover, the disruption of Aur A/B blocked abnormal cytokinesis and decreased cell
multinuclearity and chromosome tetraploidy, whereas the deprivation of BRCA1/2 promoted the abnormal cytokinesis
and enhanced the cell multinuclearity and tetraploidy. Furthermore, we showed by animal assays that the depletion of
Aur A/B inhibited tumor growth of both cell lines, while the knockdown of BRCA1/2 promoted the tumor growth.
However, the concurrent silencing of Aur A/B and BRCA1/2 diminished the effects of these molecules on the regulation
of cell cycle, cytokinesis, and tetraploidy, leading to the burdened tumor sizes similar to those induced by scrambled
shRNA-treated control cells. In summary, our study revealed that the negative interplay between Aur A/B and BRCA1/2
inversely controls the cell proliferation, cell cycle progression, cell multinuclearity, and tetraploidization to modulate
tumorigenesis.
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unless otherwise stated.segregation [1]. It has been reported that the overex-
pression or amplification of Aur A/B drives chromo-
somal instability and induces tumor formation. Studies
have shown that both Aur A and Aur B promote cell
cycle progression [2,3]. Aur A is involved in cytokinesis,
and overexpression of Aur A promotes abnormal cyto-
kinesis and increases the number of polyploid cells
[2,4]. Other studies suggest that the inactivation of Aur
B promotes the completion of cytokinesis through ab-
scission and prevents against tetraploidization [5].
Breast cancer susceptibility genes 1 and 2 (BRCA1/2)
are known as tumor suppressor genes playing critical
roles in DNA repair, cell cycle checkpoint control, and
in maintenance of the genomic stability. Both BRCA1td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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Cancer cells in tissues of BRCA1 or BRCA2 mutation
carriers are usually near tetraploid/polyploidy [9,10]. In
mammary epithelial cells, blocking BRCA1 function
leads to the aberrant mitosis with binuclear and tetra-
ploidy [11]. Likewise, in murine embryo fibroblasts and
cervical cancer cells, the absence of BRCA2 impairs the
completion of cell division due to abnormal cytokinesis,
leading to chromosomal polyploidization [12].
Increasing evidences have suggested that Aur A/B and
BRCA1/2 may interplay to control the cell cycle, chromo-
some polyploidy, and tumorigenesis. For examples, Aur A
physically binds to and phosphorylates BRCA1 at Ser308,
leading to the abrogation of G2-M checkpoint [13], while
BRCA1 can in return inhibit the activity of Aur A kinase
through Gadd45a [14]. We have recently reported that
Aur A and BRCA2 are mutually suppressed in ovarian
cancer cells to control the RAS-associated genomic in-
stability and tumorigenesis through the regulation of the
cytokinesis and polyploidization [4]. Another study
showed that the overexpression of BRCA2 in breast can-
cer cells suppresses the Aur A/B expression and reduces
the number of polyploid cells [15]. Thus, Aur A/B and
BRCA1/2 may interactively control the cell cycle progres-
sion, cytokinesis, polyploidization, and tumorigenesis.
However, such an interactive regulation between Aur A/B
and BRCA1/2 remains to be illustrated.
In this study, to explore novel interactive insights be-
tween Aur A/B and BRCA1/2, we used specific shRNAs
to consecutively silence the expressions of Aur A/B and
BRCA1/2 in pancreatic and ovarian cancer cell lines,
and analyzed the cell proliferation, cell cycle progression,
cytokinesis, chromosomal polyploidy, and tumorigenesis
of resulting cells. Our results revealed that Aur A/B and
BRCA1/2 are interactively suppressed to control the can-
cer cell growth and tumorigenesis through the regulation
of the cell cycle progression, cytokinesis, and tetraploidy.
Methods
Cell lines and cell culture
Human pancreatic cancer cell line (Capan-1), ovarian
epithelial cancer cell line (OVCA433), retroviral pack-
aging cells (Phoenix amphotropic cells) and lentiviral
packaging cells (293 T cells) were purchased from
American Type Culture Collection (ATCC, America).
Cells were maintained in Dulbecco’s modified Eagle’s
medium (DMEM, Gibco), supplemented with 10% fetal
bovine serum, 2 mM l-glutamine, penicillin (100 units/ml),
and streptomycin (100 μg/ml). All cells were incubated at
37°C in an atmosphere of 5% CO2 and 95% air.
Plasmids construction and cell transfection or viral infection
To silence the expressions of Aur A, Aur B, BRCA1 and
BRCA2, the DNA oligonucleotides used to generateshRNAs against the open reading frames of their corre-
sponding mRNAs were 5′-GUCUUGUGUCCUUCAA
AUU-3′(Aur A shRNA), 5′- AGCCAUUUCAUCGUGGC
GC-3′(Aur B shRNA), 5′-AAGUACGAGAUUUAGUC
CG-3′ (BRCA1 shRNA) and 5′-ACAAUUACGAACCA
AACCG-3′ (BRCA2 shRNA). pBabe/U6-neomycin-Aur Ai,
pGIPz-puromycin-Aur Bi, pBabe/U6-zeocin-BRCA1i and
pBabe/U6-blasticidin-BRCA2i were generated according to
the previously reported method [4]. The control vectors
were similarly constructed by directly inserting a scrambled
shRNA (Scr) into the corresponding vectors [4].
Viruses from pBabe vectors were generated and
harvested as described previously [4]. Viruses from pGIPz-
puromycin-Aur Bi were generated using FuGENE 6
(Promega, San Luis Obispo, CA) and harvested according
to manufacturer’s instruction. The resulting supernatant
was used to infect target cells (Capan-1 and OVCA433) by
using a method described before. Briefly, cells were infected
twice for a total of 6 days (3 days for each infection) and
the positive clones were selected with puromycin
(200 ng/mL), neomycin (0.5-2.5 mg/ml), zeocin (100–
750 μg/ml), or blasticidin (3–10 μg/ml) for 10–14 days to
establish new stable cell lines.
The resulting cell lines were used later for various ana-
lyses, including immunoblotting, immunofluorescence
and cell cycle.
Real time fluorescence quantitative polymerase chain
reaction
To analyze mRNA expression in cells, qRT-PCR analysis
was performed as previously described [16]. Briefly, total
RNA was isolated with Trizol reagent (Invitrogen, Carlsbad,
CA). All RNAs were then reverse transcribed into cDNAs
using the ExScript RT-PCR kit (TaKaRa, Japan) following
the manufacturer’s instructions. Oligonucleotide primer
pairs for Aur A, Aur B, BRCA1, BRCA2 and GAPDH are
described in Additional file 1: Table S1. All amplifications
and detections were carried out in the Applied Biosystems
Prism 7900 system (Applied Biosystems, Foster City, CA)
using the ExScript Sybr green QPCR kit (TaKaRa) and the
following program: 1 cycle of 30 sec at 95°C followed by
40 cycles of (5 sec at 95°C, 20 sec at 60°C), followed by a
30-min melting curve collection, which was used to verify
the primer dimers. Statistical analyses were performed
using the 2-△△CT relative quantification method. The as-
says were repeated three times in triplicate.
Cell proliferation and colony formation assay
The cell proliferation was measured by 3-(4,5-Dimethyl-
thiazol-2-yl)-2,5-Diphenyltetrazolium Bromide (MTT)
Assay. 4 × 103 cells for Capan-1 and 3 × 103 cells for
OVCA433 in 200 μl medium were incubated in 96-well
culture plates. Cell growth was detected using MTT re-
agent with Synergy H4 Hybrid Reader. Briefly, the culture
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0.5 mg/ml MTT in 200 μl medium was added to each well
and incubated for 4 h, followed by treatment with 150 μl
of DMSO for 10 min. Data were collected by measuring
the absorbance of optical density (OD) at 570 nm and
subtracted from the background OD at 490 nm. The as-
says were repeated three times in triplicate.
For plate colony formation, 250 cells were seeded in 6-
well plate. Duplicate cultures of each cell type were
maintained at 37°C in a 5% CO2 atmosphere, and fresh
medium was fed every 7 days. The number of colonies
with >50 cells in each well was counted at 14 to 21 days.
The assays were repeated three times.
Cell cycle analysis
Cells (1–2 × 106) were harvested, washed twice with 1 ×
PBS. The cells were fixed with 4 ml of cold 75% ethanol
at −20°C overnight and then washed twice with 1 × PBS.
The cells were then resuspended in 500 μl of 1× PBS
and stained with 200 μl of propidium iodide (50 μl/ml;
Sigma-Aldrich, Missouri, US) and 20 μl of RNase (1 mg/
ml; Sigma-Aldrich, Missouri, US) in a 37°C water bath
for 15 to 20 minutes. Cell cycles were determined by
FAC Station (Beckman Coulter, FV500) and analyzed by
using Kaluza® Flow Analysis Software and a published
method. The assays were repeated three times.
Immunoblotting
To analyze protein expression in cells, immunoblotting
analysis was performed as previously described [2].
Antibodies against the following proteins were obtained
from Santa Cruz Technology (California, US): Aur A
(sc-25425), Aur B (sc-25426), BRCA1 (sc-6954), CDK2
(sc-163), CDK4 (sc-260), CDK6 (sc-177), cyclin D1 (sc-
718), cyclin E (sc-247), cyclin A (SC-751). Antibodies
against BRCA2 (19791-1-AP) and cyclin B1 (cs-4135)
were obtained from Proteintech (Chicago, USA) and
Cell Signaling Technology (Massachusetts, US), respect-
ively. The detection of β-actin (A2228, Sigma Aldrich,
St. Louis, MO) was used as a loading control. The second-
ary antibodies were F(ab)2 fragments of donkey anti-mouse
immunoglobulin or of donkey anti-rabbit immunoglobulin
linked to horseradish peroxidase from Cell Signaling
Technology (Massachusetts, US). Immunoblotting reagents
were from an electrochemiluminescence kit (Amersham
Biosciences). To test whether the expression levels of pro-
teins were regulated through proteasome-mediated degrad-
ation, cells were exposed with 20 μM MG132 (#S2619,
Selleck Company, Texas, America) for 3 h and then har-
vested for Western blotting analysis.
Immunofluorescence
Immunofluorescence staining was done according to a
published protocol [2]. Primary antibodies against Aur A(sc-25425), Aur B (sc-25426), BRCA1 (sc-6954) and
BRCA2 (sc-1818) were obtained from Santa Cruz Tech-
nology (California, US). DNA dye 4′,6-diamidino-2-phe-
nylindole (DAPI) was obtained from Molecular Probes.
The secondary antibodies used were the FITC-conjugated
donkey anti-mouse IgG, cy3-conjugated donkey anti-
rabbit IgG, Texas red-conjugated or FITC-conjugated
donkey anti-goat IgG (Jackson ImmunoResearch Labora-
tory). All stained cells were examined and photographed
with a Leica SP5 confocal fluorescence microscope.
Analysis of metaphase chromosomes
Cells were cultured for 24 h and collected for chromo-
some preparation using standard procedures. Briefly, cells
were exposed to colchicine (0.1 μg/mL for OVCA433 and
0.05 μg/ml for Capan-1) for 3 h, then subjected to hypo-
tonic treatment (0.075 M KCl for 30 min at 37°C) and
fixed in a mixture of methanol and acetic acid (3:1). After
three changes of the fixative, the chromosome spreads
were prepared by dropping the cell suspension onto cold
slides, which were then air-dried. The slides were stained
with Giemsa and examined for numerical abnormalities in
the chromosomes. 3 slides and 30–36 metaphase spreads
in each slide were analyzed for each cell line. The assays
were repeated three times.
Xenograft tumors in nude mice
To generate tumor growth in vivo, 5 × 106 cells of each
cell line were subcutaneously injected into 4- to 6-week-
old BALB/c athymic nude mice (Department of Labora-
tory Animal, Fudan University). The animal experiments
were approved by the Institutional Animal Care and Use
Committee of Fudan University and performed following
Institutional Guidelines and Protocols. Each cell line was
bilaterally injected into six mice, for a total of 12 injec-
tions. The longest diameter “a” and the shortest diam-
eter “b” of tumors were measured and the tumor
volume was calculated with the use of the following for-
mula: tumor volume (in mm3) = a × b2 × 0.52 [17], where
0.52 is a constant to calculate the volume of an ellipsoid.
When a tumor reached 2.0 cm in diameter, the mouse
were sacrificed and the tumors were weighed.
Statistical analysis
Data were statistically analyzed with the Student t test.
P < 0.05 was considered statistically significant.
Results
Interactive regulation of Aur A/B and BRCA1/2 in cancer
cells
To examine the interaction between Aur A/B and BRCA1/
2, we first analyzed the expression of these four proteins by
Western blotting in cell lines treated with corresponding
shRNAs. The results showed that the knockdown of Aur
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BRCA1 in Capan-1 cells, while the silencing of Aur B
(Aur Bi) enhanced the expression levels of Aur A and
BRCA1. The disruption of BRCA1 (BRCA1i) decreased
the expression of Aur A, but not that of Aur B. Further
knockdown of BRCA1 in cells with Aur B shRNA also
downregulated the level of Aur A. BRCA1 was elevated
in cells with concurrent silencing of Aur A and Aur B
compared with scrambled shRNA-treated cells (Scr)
(Figure 1A). These results suggested that Aur A/B and
BRCA1 was interactively regulated in BRCA2 deficient
Capan-1 cells. In ovarian cancer OVCA433 cells (Figure 1B),
the interruption of Aur A did not alter the expression of
Aur B, but the knockdown of Aur B enhanced the expres-
sion of Aur A. The silencing of Aur A or/and Aur B pro-
moted the expressions of BRCA1 and BRCA2, compared
with in scrambled shRNA-treated control cells. On the
other hand, Aur A, but not Aur B, was increased in
OVCA433-BRCA1i, OVCA433-BRCA1i-BRCA2i, and
OVCA433-BRCA1i-BRCA2i-Aur Bi cells, compared with
in scrambled shRNA-treated cells. Although BRCA1/2
was markedly reduced in OVCA433-BRCA1i-BRCA2i
cells, a partially restored expression of BRCA1/2 was de-
tected after Aur A and/or Aur B were depleted in such
cells. Thus, a negative regulation loop between Aur A/B
and BRCA1/2 was uncovered in both pancreatic and ovar-
ian cancer cell lines.
To test whether Aur A/B and BRCA1/2 are regulated
with each other through gene transcription, we first per-
formed qRT-PCR to measure the mRNA levels of Aur A/
B and BRCA1/2 in all cell lines treated with or withoutFigure 1 Expression levels of Aur A/B and BRCA1/2. A-B, Protein expre
of Aur A/B and BRCA1/2 before and after treatment with various shRNAs in
cancer cells OVCA433 (B). β-actin is used as a loading control. C-D, Relative
OVCA433 cells (D) detected by qRT-PCR compared with corresponding con
Capan-1 cells (E) and OVCA433 cells (F) treated with 20 μM MG132 for 3 hspecific shRNAs. As shown in Figure 1C and D, the
mRNA of each protein was reduced only in cell lines
treated with its specific shRNA, but was not significantly
altered in cell lines treated with non-isogenic shRNAs.
Thus, these results suggested that the regulation of pro-
teins between Aur A/B and BRCA1/2 might be at the
post-translational level other than at the transcriptional
level.
Because the proteasome-mediated protein degrad-
ation is one of the mostly characterized mechanisms in
post-translational modification of many proteins, and
increasing literatures have reported that the protein
levels of Aur A/B and BRCA1/2 could be controlled via
proteasome-mediated proteolysis [18-21], we treated
cells with MG132, an inhibitor of the 26S proteasome,
to test whether these proteins were essentially regulated
through the classic protein degradation. As shown in
Figure 1E and F, the inhibition of proteolysis by MG132
almost eliminated the divergences of protein expres-
sions induced by non-isogenic shRNAs in cells, which is
consistent with our previous result [4]. To sum up, the
negative interplay of Aur A/B and BRCA1/2 proteins
may be regulated mainly through proteasome-mediated
protein degradation.
Backward regulation of cell proliferation and colony
formation by Aur A/B and BRCA1/2
To investigate the effects of Aur A/B and BRCA1/2 on cell
proliferation and colony formation, we first tested the
growth curve of cells with or without silencing of Aur A/Bssions detected by Western Blotting showing the interactive regulation
BRCA2 deficient pancreatic cancer cells Capan-1 (A) and in ovarian
mRNA levels of Aur A/B and BRCA1/2 in Capan-1 cells (C) and
trol cells (Scr cells). E-F, The protein levels of Aur A/B and BRCA1/2 in
. β-actin is used as a loading control.
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the corresponding control cells, silencing of Aur A or/and
Aur B in Capan-1 cells restrained the cell growth, but si-
lencing of BRCA1 promoted the cell growth. The concur-
rent depletion of Aur A and Aur B mostly inhibited the
proliferation of Capan-1 cells. However, the knockdown of
BRCA1 in Capan-1-Aur Bi or Capan-1-Aur Ai-Aur Bi
cells converted the growth inhibition caused by the silen-
cing of Aur B or Aur A/B. Similarly, in OVCA433 cells,Figure 2 Effects of Aur A/B and BRCA1/2 on cell proliferation and col
silencing of Aur A/B or/and BRCA1/2 in Capan-1 cells (A) and OVCA433 ce
of Aur A/B or/and BRCA1/2. Data were collected from three independent e
E-F, Representative images of plate colony formation.the deprivation of Aur A or/and Aur B remarkably inhib-
ited the cell growth (Figure 2B). Cells expressing BRCA1
shRNA proliferated more robustly than control cells, and
the concurrent deprivation of BRCA1 and BRCA2 further
augmented the cell proliferation. However, the silencing of
Aur A or/and Aur B in OVCA433-BRCA1i-BRCA2i cells
reduced the growth rate, compared with OVCA433-
BRCA1i-BRCA2i and OVCA433-Scr cells. These data
suggested that Aur A/B stimulates the cell growth, andony formation. A-B, Alteration of cell growth curves before and after
lls (B). C-D, Colony formation rates of cells before and after disruption
xperiments, and analyzed for statistic significance. Error bars = 95% CIs.
Wang et al. Molecular Cancer 2014, 13:94 Page 6 of 12
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A and/or Aur B following the silencing of BRCA1 and/or
BRCA2 can partially moderate the stimulated growth
caused by the inhibition of BRCA1/2.
We then detected colony formation ability of various
cell lines. Consistent with the proliferation assay, the
colony number was reduced after silencing of Aur A
and/or B, but was increased after the disruption of
BRCA1/2 in both Capan-1 and OVCA433 cells in com-
parison with scrambled shRNA-treated control cells
(Figure 2C-F). Introduction of Aur A and/or B shRNAs
into cells along with BRCA1 or/and BRCA2 shRNAs in
both pancreatic and ovarian cancer cells evidently re-
duced the number of colonies, compared with in cells
expressing BRCA1 or/and BRCA2 shRNAs only. These
results suggested that Aur A/B and BRCA1/2 may func-
tion as antagonists to inversely regulate the cell prolifera-
tion and colony formation, and that the effect of Aur A/B
and BRCA1/2 on the cell proliferation and colony forma-
tion may be enhanced by the concurrent disruption ofFigure 3 Morphological changes of OVCA433 cells. Selected images sh
interruption of Aur A/B or/and BRCA1/2. Compared with OVCA433-Scr cells
the interruption of Aur A and/or Aur B stimulated cells thinner and more d
Aur B following double knockdown of BRCA1 and BRCA2 stimulated cells g
expressions. However, cells with the concomitant silencing of four proteins
Olympus microscope.homologous partner proteins, but may be offset by the de-
pletion of counterpart proteins.
Interestingly, we found that the knockdown of Aur A/
B or/and BRCA1/2 diversified the cellular morphology
of OVCA433 cells. As shown in Figure 3, cells with the
silenced expression of Aur A or/and Aur B appeared
thinner and more dispersed than scrambled shRNA-
treated (OVCA433-Scr) control cells viewing plump and
congregate. Cells expressing BRCA1 shRNA or both
BRCA1 and BRCA2 shRNAs still appeared plump, but
scattered. OVCA433-BRCA1i-BRCA2i cells with Aur A
or Aur B shRNAs appeared thinner and flatter than
those without Aur A or/and Aur B shRNAs. However,
cells with the synchronized silencing of the four proteins
turned oblate. The above results indicate that Aur A/B
and BRCA1/2 may potentially regulate cytoskeleton-
associated proteins, leading to phenotypic alterations of
cancer cells. However, the morphological changes of
Capan-1 cells were not observed before or after the si-
lencing of Aur A/B and/or BRCA1 (data not shown).owing phenotypic changes of OVCA433 cells before or after the
, the silencing of BRCA1 or/and BRCA2 induced cells scattered, whereas
ispersed compared with control cells. The disruption of Aur A and/or
rowing thinner and flatter than cells with intact Aur A and/or Aur B
turned oblate. The images were taken at 200 ×magnification by an
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BRCA1/2
Since Aur A/B and BRCA1/2 participate in cell cycle
control, we examined the effects of interplay between
Aur A/B and BRCA1/2 on cell cycle progression. Com-
pared with in Capan-1-Scr cells, the silencing of Aur A
and/or B decreased the number of cells in S phase, but
increased the number of cells in G2-M. The disruption
of BRCA1 reduced the cell population in G0-G1 phase
and raised the number of cells in S phase, but did not
alter the cell population in G2-M phase. However, the si-
lencing of BRCA1 in Capan-1-Aur Bi or Capan-1-Aur
Ai-Aur Bi cells perceptibly stimulated the number of
cells in S phase, but reduced the number of cells in G2-
M phase (Figure 4A). In OVCA433 cells, the disruption
of Aur A or/and B augmented the number of cells in
G0-G1 phase, and diminished the number of cells in S
phase, but did not affect the cell population in G2-MFigure 4 Regulation of cell cycle progression and cell cycle-associated
detected by flow cytometry before or after silencing of Aur A/B and/or BRC
immunoblotting. Inverse regulation of p53 and cyclin A by Aur A/B and BR
as a loading control.phase. The combined silencing of Aur A and Aur B did
not yield synergistic effects on the cell cycle progression,
compared with the solo silencing of Aur A or Aur B.
Compared with control cells, the silencing of BRCA1
promoted the cell population in S phase, and limited the
percentage of cells in G2-M phase, but did not induce
any changes of cell proportion in G0-G1 phase. The
concurrent silencing of BRCA1 and BRCA2 profoundly
reduced the number of cells in G0-G1 phase, and en-
hanced the cell population in S phase. However, the de-
pletion of Aur A and/or Aur B in BRCA1 and BRCA2
shRNAs-treated cells increased the number of cells in
G0-G1 phase and lessened the number of cells in S
phase, compared within cells without Aur A or/and Aur
B shRNAs (Figure 4B).
To validate the cell cycle alteration induced by the
interruption of Aur A/B and BRCA1/2, we tested the
major proteins involved in cell cycle regulation byproteins by Aur A/B and BRCA1/2. A-B, Cell cycle distributions
A1/2. C-D, Alteration of cell cycle regulatory proteins tested by
CA1/2 in both Capan-1 and OVCA433 cells is conceived. β-actin is used
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trol) cells, the silencing of Aur A or Aur B enhanced the
expression of p53, and attenuated the expressions of
CDK6, cyclins D1, E, A, and B1 (Figure 4C). The con-
current silencing of Aur A and Aur B up-regulated the
p53 expression, down-regulated the levels of CDK6,
cyclins D1, E, and A, but enhanced the CDK4 and cyclin
B1 expressions. The interruption of BRCA1 in Capan-1
cells decreased the expressions of p53, CDK6, cyclins
D1, E, and B1 compared with in control cells. The dis-
ruption of both BRCA1 and Aur B blocked the expres-
sions of p53 and cyclin B1, while lifted the expressions
of CDK4, CDK6, CDK2, cyclins D1, E, and A in the
resulting cells, compared with in cells expressing Aur B
shRNA alone. However, the depletion of BRCA1 in
Capan-1-Aur Ai-Aur Bi cells elevated the expressions of
CDK6, but dropped the expressions of p53, cyclins D1,
E, and B1 in Capan-1-Aur Ai-Aur Bi-BRCA1i cells. Col-
lectively, the knockdown of Aur A/B mainly promoted
the p53 expression but lessened the levels of most CDKs
and cyclins to restrain the cell cycle progression of
Capan-1 cells, while the disruption of BRCA1 inhibited
p53 to promote the cell cycle progression.
The effects by the knockdown of Aur A/B or/and
BRCA1/2 on the expressions of above proteins in
OVCA433 cells (Figure 4D) were similar to those in
Capan-1 cells. Compared with in OVCA433-Scr cells,
the silencing of Aur A lifted the levels of p53, CDK4,
cyclin E, but reduced the levels of cyclins A and B1 in
OVCA433-Aur Ai cells. The silencing of Aur B pro-
moted the expressions of p53, CDK4, CDK6, CDK2, and
cyclin B1, but inhibited the expression of cyclin A in
OVCA433-Aur Bi cells. Further silencing of Aur B in
OVCA433-Aur Ai cells strengthened the levels of p53,
CDK4, and cyclin E and B1, but largely reduced the
levels of CDK6 in OVCA433-Aur Ai-Aur Bi cells. On
the other hand, compared with in OVCA433-Scr cells,
the depletion of BRCA1 did not alter the p53 expression,
but up-regulated the CDK4 expression in OVCA433-
BRCA1i cells. Further deleting of BRCA2 in OVCA433-
BRCA1i cells increased the cyclin E expression, but
slightly decreased the cyclin B1 expression the levels of
p53, CDK4, CDK6, cyclin D1, and cyclin A were not
conceivably changed. However, the disruption of Aur A
in OVCA433-BRCA1i-BRCA2i cells enhanced the levels
of p53, CDK4, CDK6, cyclin D1, CDK2, and cyclin B1,
but blocked the expressions of cyclins E and A. The
knockdown of Aur B in OVCA433-BRCA1i-BRCA2i
cells diminished the levels of CDK4, CDK6, CDK2,
cyclins D1, E, and A, but did not alter the level of p53.
Moreover, the concurrent depletion of Aur A and B in
OVCA433-BRCA1i-BRCA2i cells reduced the levels of
CDK4, CDK6, CDK2, cyclin D1, E and A, which con-
verted the changes of these proteins, suggesting thatthese proteins may be regulated by the interplay between
Aur A/B and BRCA1/2.
To sum up, the expression of the cell cycle regulatory
proteins including p53, CDK4, CDK6, cyclin D1, CDK2,
cyclin E, cyclin B1, and cyclin A could be effectively reg-
ulated by Aur A/B and BRCA1/2 to control the cell
cycle progression, and Aur A/B and BRCA1/2 may
modulate the cell cycle fundamentally through p53 and
cyclin A.
Counter impacts of Aur A/B and BRCA1/2 on cell
multinuclearity and tetraploidy
Counts of cells with two or more nuclei showed that the
number of cells with multinuclearity was lower in
Capan-1-Aur Ai/Aur Bi or OVCA433-Aur Ai/Aur Bi
cells than in Capan-1-Scr or OVCA433-Scr cells. Cells
with the concomitant silencing of Aur A and Aur B in
Capan-1- or OVCA433-Aur Ai-Aur Bi cells appeared
with more multinuclearity than those with the solo de-
pletion of Aur A or Aur B in Capan-1- or OVCA433-
Aur Ai/Bi cells (Figure 5A-B). The deprivation of
BRCA1 increased the proportion of cells with multiple
nuclei in Capan-1- or OVCA433-BRCA1i cells. How-
ever, compared with in Capan-1-Aur Ai-Aur Bi cells,
the cell multinuclearity was not markedly increased in
Capan-1-Aur Ai-Aur Bi-BRCA1i cells (Figure 5A). The
diminution of BRCA2 in OVCA433-BRCA1i-BRCA2i
cells enhanced the proportion of cells with multiple nuclei
compared with in OVCA433-BRCA1i cells. However, the
intervention of Aur A or/and Aur B in OVCA433-
BRCA1i-BRCA2i cells salvaged the functional effects of
BRCA1/2 on suppression of the cell multinuclearity in
OVCA433-BRCA1i-BRCA2i-Aur Ai, OVCA433-BRCA1i-
BRCA2i-Aur Bi, OVCA433-BRCA1i-BRCA2i-Aur Ai-Aur
Bi cells (Figure 5B).
Abscission is the last step of cytokinesis and the re-
strained abscission causes cytokinesis failure, resulting in
cells with the multinuclearity and tetraploidy. Since Aur
A/B and BRCA1/2 have been reported to be accumu-
lated at midbody during the cytokinesis of late mitosis
[4,5,22,23], we detected these proteins by immunofluor-
escence. As shown in Figure 5C, both Aur A and Aur B
were localized at the midbody during the late telophase
in Capan-1 cells, but only a few of BRCA1 protein was
observed at the midbody. The diminution of Aur A or
BRCA1 slightly increased the expression of Aur B at the
midbody. Aur A/B and BRCA1/2 co-localized at the
midbody during the late telophase, but the staining of
BRCA1 was faint in OVCA433 cells. The interruption of
Aur A/B enhanced the BRCA2 accumulation at the mid-
body, but did not conceivably modify the staining of
BRCA1. On the other hand, the revoking of BRCA2 fol-
lowing the BRCA1 knockdown dramatically enhanced
the Aur A/B accumulation at the midbody (Figure 5D).
Figure 5 Regulation of polyploidy and cytokinesis by Aur A/B and BRCA1/2. A-B, Quantification of cells with multiple nuclei before or after
the depletion of Aur A/B and BRCA1/2. Error bars = 95% CIs, indicating data were collected from three independently repeated experiments. C-D,
Representative images showing the localization and accumulation of Aur A/B and BRCA1/2 at the midbody during cytokinesis (×1000). Blue dye
DAPI indicates nucleus. Scale bars, 5 μm for the merged images and 1 μm for other images. E-F, Representative images of karyotypes before and
after the silencing of Aur A/B or/and BRCA1/2 in Capan-1 cells (E) and OVCA433 cells (F).
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http://www.molecular-cancer.com/content/13/1/94Thus, Aur A/B and BRCA2 may inversely regulate cyto-
kinesis to control the cell tetraploidization.
Analysis of chromosome karyotyping showed that the
silencing of Aur A and/or B reduced the proportion of
tetraploid cells in both Capan-1 and OVCA433 cells than
that in control cells. The disruption of BRCA1 or/and
BRCA2 in Capan-1 or OVCA433 cells resulted in more
tetraploid than did in control cells. The depletion of
BRCA1 in Capan-1-Aur Ai-Aur Bi cells promoted tetra-
ploidy in Capan-1-Aur Ai-Aur Bi-BRCA1i cells. Add-
itional deprivation of Aur A and/or Aur B in OVCA433-
BRCA1i-BRCA2i cells reduced the level of tetraploidy in
OVCA433-BRCA1i-BRCA2i-Aur Ai, OVCA433-BRCA1i-
BRCA2i-Aur Bi and OVCA433-BRCA1i-BRCA2i-Aur
Ai-Aur Bi cells (Table 1, Figure 5E-F).
Opposite function of Aur A/B and BRCA1-2 in
tumorigenesis
To test how Aur A/B and BRCA1/2 affect tumor growth,
we injected Capan-1 and OVCA433 cells expressing vari-
ous shRNAs along with their control cells into nude mice
and analyzed the tumor growth. As shown in Figure 6A
and C, the knockdown of Aur A or Aur B in Capan-1 cells
inhibited the tumor growth, but the silencing of BRCA1
alone promoted the tumor growth in mice, compared
with relative control cells. Tumors burdened in animals
injected with Capan-1-Aur Ai-Aur Bi cells were smaller
than any other tumors derived from Capan-1 cells
treated with shRNAs. The volumes of tumors induced
with Capan-1-Aur Bi-BRCA1i or Capan-1-Aur Ai-AurBi-BRCA1i cells were bigger than those with Capan-1-
Aur Bi, or Capan-1-Aur Ai-Aur Bi cells. Similarly, the
tumors generated with OVCA433 cells treated with Aur
A and/or Aur B shRNAs developed more slowly, but
those generated with cells expressing BRCA1 and/or
BRCA2 shRNAs advanced much faster than tumors
produced with control cells (Figure 6B and D). Among
tumors derived from OVCA433 cells, those inoculated
with OVCA433-BRCA1i-BRCA2i cells were the most
robust, but those derived from OVCA433-Aur Ai-Aur
Bi cells were the slowest. These results suggest that Aur
A/B and BRCA1/2 manage tumorigenesis in an opposite
manner, and that the effects on tumorigenesis by dis-
rupting one protein can be synergized by depleting the
other homolog or can be diminished by silencing one of
the counterpart proteins.
Discussion
The control of cell cycle in normal cells plays a key role
in maintaining genetic fidelity during cell division. Any
errors occurred during cell cycle progression may cause
chromosome abnormalities, leading to cell aneuploidy or
polyploidy, and subsequent tumorigenesis. It has been
reported that the elevated Aur A promotes G1-S and
G2-M transition [2], while silencing of Aur B results in
acute cell cycle arrest in G1 phase [24]. Phosphorylation
of BRCA1 at S308 by Aur A in the M phase is an early
event necessary for G2-M transition [13]. Loss of
BRCA1/2 leads to override of M phase, multinucleation
and tetraploidy/polyploidy [9,10]. We showed that, in
Table 1 Aur A/B and BRCA1/2 mediate cell polyploidy
Cell lines1 Diploidy cells (%) Tetraploidy cells (%) N2
Capan-1 Scr 78.6 ± 3.2 16.2 ± 3.3 302
Aur Ai 82.3 ± 3.9 (*S↑) 11.6 ± 5.1 (*S↓) 300
Aur Bi 87.3 ± 5.9 (*S↑) 10.6 ± 4.6 (*S↓) 302
BRCA1i 72.8 ± 6.1 (*S↓) 22.3 ± 6.4 (*S↑) 303
Aur Ai-Aur Bi 89.0 ± 4.7 (*S↑) 6.4 ± 3.9 (*S↓) 306
Aur Bi-BRCA1i 83.4 ± 5.0 (*S↑) 9.3 ± 6.7 (*S↓) 303
Aur Ai-Aur Bi-BRCA1i 78.0 ± 4.8 (*AB↓) 10.0 ± 4.7 (*AB↑) 299
OVCA433 Scr 88.9 ± 4.5 11.1 ± 4.5 287
Aur Ai 95.0 ± 5.0 (*S↑) 5.0 ± 5.0 (*S↓) 298
Aur Bi 95.0 ± 2.1 (*S↑) 5.0 ± 2.1 (*S↓) 302
BRCA1i 80.0 ± 6.3 (*S↓) 20.0 ± 6.3 (*S↑) 295
Aur Ai-Aur Bi 97.8 ± 2.4 (*S↑) 2.2 ± 2.4 (*S↓) 300
BRCA1i-BRCA2i 77.8 ± 6.1 (*S↓) 22.2 ± 6.1 (*S↑) 290
BRCA1i-BRCA2i-Aur Ai 90.0 ± 4.2 (*B1B2↑) 10.0 ± 4.2 (*B1B2↓) 294
BRCA1i-BRCA2i-Aur Bi 84.6 ± 4.7 (*B1B2↑) 14.4 ± 4.9 (*B1B2↓) 290
BRCA1i-BRCA2i-Aur Ai-Aur Bi 91.2 ± 4.8 (*B1B2↑) 7.8 ± 5.6 (*B1B2↓) 290
1For each cell line, 30–36 cells in metaphase in every slide were examined. The assays were repeated three times. The increase or decrease of cells with diploidy or
tetraploidy was indicated as “↑” or “↓”, respectively. * p < 0.05. S, AB or B1B2 represent cells expressing Scr, Aur Ai-Aur Bi or BRCA1i-BRCA2i used for statistical analysis.
2 N represents the total number (N) of cells karyotyped for each cell line.
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http://www.molecular-cancer.com/content/13/1/94this study, the silencing of Aur A/B suppressed overall
cell cycle progression mainly through G1-S and G2-M
transition, while the disruption of BRCA1/2 mainly pro-
moted cell cycle progression through accelerated G1-S
and G2-M transition, suggesting that Aur A/B andFigure 6 Xenograft tumor growth in animals. A-B, The mean volume o
expressing scrambled shRNA or different shRNAs against Aur A/B or BRCA1
tumor formed in different groups of mice. Error bars = 95% CIs. *P < 0.05, **BRCA1/2 negatively regulate G1-S and G2-M transitions
to control cell cycle progression. Furthermore, we found
that the expression of p53 was negatively regulated by
Aur A/B, but positively regulated by BRCA1/2, which
was consistent with previous studies [25,26], indicatingf tumors burdened in mice receiving Capan-1 or OVCA433 cells
/2. Error bars = 95% CIs. *P < 0.05. C-D, The average weight of each
P < 0.01.
Wang et al. Molecular Cancer 2014, 13:94 Page 11 of 12
http://www.molecular-cancer.com/content/13/1/94that p53 might be the focused target of both Aur A/B
and BRCA1/2 through which to modulate cell cycle pro-
gression and tetraploidization. Moreover, studies have
shown that cyclin A is essential for the G1-S and G2-M
transitions [27], and that cyclin A availability is the rate-
limiting step for entry into mitosis [28]. We found that
the disruption of Aur A/B down-regulated cyclin A ex-
pression, but the silencing of BRCA1/2 up-regulated
cyclin A. Therefore, cyclin A may be another mediator
regulated conversely by Aur A/B and BRCA1/2 to control
cell proliferation, cell cycle progression, and tumorigenesis.
Complete mitosis is composed of nuclei division and
cytoplasm separation - cytokinesis. The last step of cyto-
kinesis is the abscission of midbody, the failure of which
is associated with delayed cytokinesis and ploidy changes
[29]. Inactivation of Aur B promotes completion of cyto-
kinesis by abscission to suppress tetraploidization [5].
BRCA2 interacts with many abscission factors at the
midbody, and the disruption of these abscission factors
results in increased cytokinetic defects [22]. We previ-
ously reported that Aur A inversely regulates BRCA2 at
the midbody during cytokinesis to promote polyploidy
[4]. In this study, we showed that Aur A/B and BRCA2
were co-localized at midbody and conversely regulated
the counterparts during late mitosis, indicating that the
interplay of Aur A/B and BRCA2 may manipulate cyto-
kinesis to keep a proper segregation of two daughter
cells from polyploidy. Additionally, as reported, although
no BRCA1 staining was observed at the midbody in im-
munofluorescence slides of cervical cancer cells HeLa
[30], evident localization of BRCA1 was found in the
midbody area during cytokinesis in immunoelectron-
microscopic sections of breast cancer cells SKBR3 [23].
In this study, the staining of BRCA1 at the midbody of
mitotic Capan-1 cells was not strong, and the knock-
down of Aur A/B did not fortify the accumulation of
BRCA1 at the midbody, indicating that the role of
BRCA1 at the midbody may be less valuable. However,
we did find that the silencing of BRCA1 promoted cell
tetraploidization, indicating that BRCA1 may regulate
tetraploid through a different way, for example the regu-
lation of centrosome. More importantly, the concurrent
silencing of Aur A, Aur B, BRCA1, and BRCA2 did not
induce complete cytokinesis failure in both Capan-1 and
OVCA433 cells, implying that some other factors such
as survivin and HIPK2 It is well-known that the
proteasome-mediated degradation may still function to
maintain cytokinesis [31,32].
Is one of the possible mechanisms in the post-translation
regulation proteins. The mounting studies have evidenced
that the expression levels of Aur A/B and BRCA1/2 may be
also controlled through ubiquitin-mediated protein degrad-
ation. For instances, FBXW7, a component of E3 ubiquitin
ligase, can target both Aur A and Aur B for ubiquitinationand subsequent degradation [18,19]. BRCA1 forms a het-
erodimer with BRCA1-associated RING domain 1
(BARD1) and exhibits the E3 ubiquitin ligase activity to tar-
get other proteins [33], while the Aur A kinase functions to
inhibit the E3 ubiquitin ligase activity of BRCA1 [34].
Moreover, BRCA1/2 may interact with Aur B through the
BRCA1-associated ring domain protein 1 (BARD1) to
modulate the mitotic spindle formation, cytokinesis, aneu-
ploidy and genomic instability [30]. BARD1β, an isoform of
BARD1 deficient of RING domain, stabilizes Aur B and
forms a complex with BRCA2 and Aur B [30]. In this study,
by qRT-PCR and cell treatment with MG132, we showed
that the interactive regulation of protein expressions be-
tween Aur A/B and BRCA1/2 was mainly controlled
through the proteasome-mediated proteolysis although the
detailed mechanism may need more investigations.
In conclusion, the interplay of Aur A/B and BRCA1/2
constitutes a regulatory network in cancer development.
A schematic diagram in Additional file 2: Figure S1 is to
illustrate that Aur A/B and BRCA1/2 were negatively
regulated between each other likely through proteasome-
mediated proteolysis (PMP) to control cell proliferation,
cell cycle progression, cytokinesis, tetraploid, and eventu-
ally tumorigenesis of cancer cells. Molecules including
p53 and cyclin A may be the major mediators inversely
regulated by imbalanced expressions of Aur A/B and
BRCA1/2 in cancer cells. Although the interactive regula-
tion between Aur A/B and BRCA1/2 may lie in different
pathways such as proteolysis as we reported [4], this study
may have provided some novel insights that the negative
interplay between Aur A/B and BRCA1/2 plays an essen-
tial role during cancer development. The results of this
study may be used to improve the efficacy of the current
therapeutic methods in cancers specifically with amplified
Aur A/B and inactivated BRCA1/2.
Additional files
Additional file 1: Table S1. Sequences of oligonucleotide primer pairs
for qPCR.
Additional file 2: Figure S1. A schematic diagram illustrates how Aur A/
B and BRCA1/2 regulate cell cycle progression and cytokinesis to modulate
tetraploidy and tumorigenesis. PMP: proteasome-mediated proteolysis.
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